Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential...
COVID-19
Microbot Medical Announces MedTech Industry Veteran Joe Mullings will Moderate the Next ‘Access-Ability Live by MBOT’ Webinar
Panel of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Personal Experiences of Taking Innovative New Technologies...
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a...
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara®...
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab)...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech...
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
TCR² Therapeutics Announces Pipeline Priorities for 2023
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation...
Newsight Imaging and First International Computer Announce Partnership for LiDAR solution for Automotive Safety
Co-development of 3D Vision System Solutions to Facilitate Rapid Development and Fast Time-to-Market of New ProductsLAS VEGAS , Jan. 05,...
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in...
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK,...
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults...
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology...
EDAP Announces Record Q4 US Focal One Placements
Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP...
ORYZON to Give Updates on Corporate Progress in January
6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum...
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalSINGAPORE and...
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and...
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04,...